Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26047508 | 0.85 | ACSS2 (0.47) | ACSS2MAPK1RIPK1CACNA1HMAP3K5 | |
| SCHEMBL26047502 | 0.85 | ACSS2 (0.46) | ACSS2MAPK1RIPK1MAP3K5 | |
| SCHEMBL26046870 | 0.84 | ACSS2 (0.46) | ACSS2RIPK1 | |
| SCHEMBL23843413 | 0.82 | ACSS2 (0.67) | ACSS2 | |
| SCHEMBL26047459 | 0.82 | ACSS2 (0.45) | ACSS2RIPK1 | |
| SCHEMBL26046859 | 0.81 | ACSS2 (0.64) | ACSS2MAPK1RIPK1PABPC1MAP3K5 | |
| SCHEMBL26047485 | 0.80 | ACSS2 (0.57) | ACSS2MAPK1RIPK1PABPC1 | |
| SCHEMBL26047387 | 0.80 | ACSS2 (0.71) | ACSS2MAPK1RIPK1PABPC1MAP3K5 | |
| SCHEMBL26047384 | 0.79 | ACSS2 (0.70) | ACSS2MAPK1PABPC1 | |
| SCHEMBL26047413 | 0.79 | ACSS2 (0.54) | ACSS2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | BRCA1, HRAS, PCNA | ACSS2 201/4885MAPK1 1741/4885RIPK1 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.